Prakash Vishnu

2.0k total citations · 1 hit paper
67 papers, 1.4k citations indexed

About

Prakash Vishnu is a scholar working on Hematology, Oncology and Surgery. According to data from OpenAlex, Prakash Vishnu has authored 67 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Hematology, 21 papers in Oncology and 15 papers in Surgery. Recurrent topics in Prakash Vishnu's work include Platelet Disorders and Treatments (13 papers), Lymphoma Diagnosis and Treatment (10 papers) and Heparin-Induced Thrombocytopenia and Thrombosis (9 papers). Prakash Vishnu is often cited by papers focused on Platelet Disorders and Treatments (13 papers), Lymphoma Diagnosis and Treatment (10 papers) and Heparin-Induced Thrombocytopenia and Thrombosis (9 papers). Prakash Vishnu collaborates with scholars based in United States, Germany and Switzerland. Prakash Vishnu's co-authors include David M. Aboulafia, Vivek Roy, Aneel A. Ashrani, Stanislav Henkin, Euphemia Leung, Charles L. Loprinzi, Alfonso Tafur, Robert D. McBane, Charles Kuzma and Usha Perepu and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Gastroenterology.

In The Last Decade

Prakash Vishnu

58 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial

2019 375 citations Robert D. McBane, Waldemar E. Wysokiński et al. Journal of Thrombosis and Haemostasis profile →

Peers

Countries citing papers authored by Prakash Vishnu

Since Specialization

Citations

This map shows the geographic impact of Prakash Vishnu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Prakash Vishnu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Prakash Vishnu more than expected).

Fields of papers citing papers by Prakash Vishnu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Prakash Vishnu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Prakash Vishnu. The network helps show where Prakash Vishnu may publish in the future.

Co-authorship network of co-authors of Prakash Vishnu

This figure shows the co-authorship network connecting the top 25 collaborators of Prakash Vishnu. A scholar is included among the top collaborators of Prakash Vishnu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Prakash Vishnu. Prakash Vishnu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comparison of Trifecta and Pentafecta Outcomes across 3 Surgical Modalities of Partial Nephrectomy (PN) – Open, Lap, and Robotic 2024 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), Prakash Vishnu, (unknown), Anil Kumar, Yogesh N.V. Reddy, (unknown)	0
2	Proteomic profiling for biomarker discovery in heparin-induced thrombocytopenia 2024 ·Blood Advances ·(unknown), Hind Hamzeh‐Cognasse, Janna Hastings, Jan–Dirk Studt, Dimitrios A. Tsakiris, Andreas Greinacher, (unknown), (unknown), Walter A. Wuillemin, B. Gerber, Prakash Vishnu, Lukas Graf, Johanna A. Kremer Hovinga, Tamam Bakchoul, Fabrice Cognasse, Michael Nagler	5
3	OSTEOPOROSIS WITH SPECIAL REFERENCE TO ASTHIKSHAYA, A PREVALENCE ASSESSMENT 2024 ·International Journal of Advanced Research ·Prakash Vishnu, (unknown), (unknown)	0
4	Removal of Fluorides Using a Low-Cost Adsorbent 2023 ·Narayanam Srikanth, (unknown), (unknown), (unknown), (unknown), (unknown), Prakash Vishnu	1
5	A machine-learning model for reducing misdiagnosis in heparin-induced thrombocytopenia: a prospective, multicenter, observational study 2022 ·EClinicalMedicine ·(unknown), Adam Cuker, S. Haug, Christos T. Nakas, Jan–Dirk Studt, Dimitrios A. Tsakiris, Andreas Greinacher, (unknown), (unknown), Walter A. Wuillemin, B. Gerber, Johanna A. Kremer Hovinga, Prakash Vishnu, Lukas Graf, (unknown), Raphael Sznitman, Tamam Bakchoul, Michael Nagler	21
6	Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia 2019 ·Blood Cancer Journal ·Vivek Kumar, Sikander Ailawadhi, (unknown), Aditya Mehta, (unknown), Taimur Sher, Vivek Roy, Prakash Vishnu, Julian A. Marin‐Acevedo, Victoria R. Alegria, Aneel Paulus, (unknown), Madiha Iqbal, Rami Manochakian, Winston Tan, Asher Chanan‐Khan, (unknown)	44
7	Etiologies of Extreme Thrombocytosis: A Contemporary Series 2019 ·Mayo Clinic Proceedings ·Ronan W. Hsieh, Aishwarya Ravindran, C. Christopher Hook, Kebede H. Begna, Aneel A. Ashrani, Rajiv K. Pruthi, Ariela L. Marshall, William J. Hogan, Mark R. Litzow, James D. Hoyer, Jennifer L. Oliveira, Prakash Vishnu, Timothy G. Call, Aref Al‐Kali, Mrinal M. Patnaik, Naseema Gangat, Animesh Pardanani, Ayalew Tefferi, Ronald S. Go	10
8	Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial breakdown → 2019 ·Journal of Thrombosis and Haemostasis ·Robert D. McBane, Waldemar E. Wysokiński, Jennifer Le‐Rademacher, Tyler Zemla, Aneel A. Ashrani, Alfonso Tafur, Usha Perepu, Daniel M. Anderson, Krishna Gundabolu, Charles Kuzma, Juliana Perez Botero, Roberto A. Leon Ferre, Stanislav Henkin, Charles J. Lenz, Damon E. Houghton, Prakash Vishnu, Charles L. Loprinzi	375
9	Myelodysplasia-related acute myeloid leukemia and acute promyelocytic leukemia: concomitant occurrence of two molecularly distinct diseases 2018 ·Hematology Reports ·(unknown), Abdel‐Ghani Azzouqa, David M. Menke, James M. Foran, Prakash Vishnu	3
10	Pharmacokinetics-based clinical management of acquired von Willebrand syndrome: a case report 2018 ·Journal of Blood Medicine ·(unknown), Candido E. Rivera, Han W. Tun, Prakash Vishnu	2
11	DA.R-EPOCH Vs. R-CHOP for High-Risk Diffuse Large B- Cell Lymphoma: The Mayo Clinic Florida Experience 2017 ·Blood ·Bhagirathbhai Dholaria, Prakash Vishnu, Vivek Roy, Han W. Tun, Taimur Sher, Candido E. Rivera, Sikander Ailawadhi, Nancy N. Diehl, David O. Hodge, (unknown)	0
12	Guidelines in Clinical Practice: Appraisal of Quality Metrics in the Management of Newly Diagnosed Diffuse Large B-Cell Lymphoma Based on the American Society of Hematology Practice Improvement Module 2017 ·Blood ·(unknown), Prakash Vishnu, Margaret T. Mandelson, David M. Aboulafia	1
13	Immune Reconstitution Inflammatory Syndrome-Associated Burkitt Lymphoma After Combination Antiretroviral Therapy in HIV-Infected Patients 2014 ·Clinical Lymphoma Myeloma & Leukemia ·Prakash Vishnu, (unknown), David M. Aboulafia	6
14	Lymphoproliferative disorders following solid organ transplantation 2013 ·Surgery Current Research ·Prakash Vishnu	0
15	NEEDLE FREE INJECTION TECHNOLOGY: A REVIEW 2012 ·International Journal of Pharmacy ·Prakash Vishnu, (unknown), (unknown), (unknown), (unknown)	5
16	Effect of Leuprolide on Serum Amyloid-β Peptide Levels and Memory in Patients With Prostate Cancer With Biochemical Recurrence 2012 ·Urology ·Winston Tan, Michael G. Heckman, Prakash Vishnu, Julia E. Crook, Linda H. Younkin, (unknown), Tanis J. Ferman, Neill R. Graff‐Radford, Steven G. Younkin, Robert C. Smallridge, Michael J. Wehle, Steven J. Buskirk	7
17	RhoB mediates antitumor synergy of combined ixabepilone and sunitinib in human ovarian serous cancer 2011 ·Gynecologic Oncology ·Prakash Vishnu, Gerardo Colón‐Otero, Gregory T. Kennedy, Laura A. Marlow, William P. Kennedy, Kevin J. Wu, Joseph T. Santoso, John A. Copland	14
18	Plasmacytoma-like Posttransplant Lymphoproliferative Disorder Following Orthotopic Liver Transplantation: A Case Report 2011 ·Transplantation Proceedings ·Prakash Vishnu, Jiang Liu, Cherise Cortese, David M. Menke, Han W. Tun	5
19	Autoantibody Profiles Reveal Ubiquilin 1 as a Humoral Immune Response Target in Lung Adenocarcinoma 2007 ·Cancer Research ·Guoan Chen, Xiaoju Wang, Jianjun Yu, Sooryanarayana Varambally, Jindan Yu, Dafydd G. Thomas, Mu-Yen Lin, Prakash Vishnu, Zhuwen Wang, Rui Wang, (unknown), Debashis Ghosh, Thomas J. Giordano, Donald Giacherio, Andrew C. Chang, Mark B. Orringer, Talal El‐Hefnawy, William L. Bigbee, David G. Beer, Arul M. Chinnaiyan	73
20	P2-220: Radiation pneumonitis (RP) in lung cancer patients treated with chemotherapy (CT) and thoracic radiation (TR): Retrospective analyses of patients treated at a comprehensive cancer center 2007 ·Journal of Thoracic Oncology ·Prakash Vishnu, Sridhar Srinivasan, (unknown), Andrew T. Turrisi, Lance K. Heilbrun, (unknown), (unknown), Ayman O. Soubani, Shirish M. Gadgeel	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact